公开(公告)号：EP3164157A2

公开(公告)日：2017-05-10

申请号：EP15814551.6

申请日：2015-07-01

申请人： Vicus Therapeutics, LLC

发明人： MAKI, John ,  BASCOMB, Newell ,  YOUNG, Fredric

IPC分类号： A61K49/00 ,  A61K47/00 ,  A61K9/00 ,  C08G79/00 ,  A61L27/52 ,  C01B33/152

CPC分类号： A61K47/42 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/138 ,  A61K31/407 ,  A61K38/2013 ,  A61K45/06 ,  A61K2300/00

摘要： In alternative embodiments, provided are pharmaceutical compositions, formulations, kits and other products of manufacture, comprising a sterile hydrogel comprising a hydrogel material and active ingredients including one or a plurality of compositions or compounds, which may comprise: a biologic, a drug or an immunostimulating agent or reagent; an antigen or an immunogen, or a plurality of antigens or immunogens; an anticancer agent or reagent, or any combination thereof.

摘要翻译： 在可替代的实施方案中，提供药物组合物，制剂，试剂盒和制造的其他产品，包括无菌的水凝胶包括水凝胶材料和活性成分，包括一种或组合物或化合物的复数，其可以包括：一个生物，药物或 免疫刺激剂或试剂; 抗原或免疫原性，或抗原或免疫原的多元性; 在抗癌剂或试剂，或它们的任何组合。

公开(公告)号：EP3028743A3

公开(公告)日：2017-01-25

申请号：EP15191023.9

申请日：2009-03-05

申请人： Vicus Therapeutics, LLC

发明人： BASCOMB, Newell ,  MAKI, John ,  YOUNG, Frederic

IPC分类号： A61P35/00 ,  A61K31/195 ,  A61K45/06 ,  A61K31/00 ,  A61K31/407 ,  A61K31/138

CPC分类号： A61K39/39558 ,  A23L33/10 ,  A23V2002/00 ,  A61J1/035 ,  A61J1/10 ,  A61J3/02 ,  A61J3/06 ,  A61J3/07 ,  A61J3/08 ,  A61J3/10 ,  A61J7/0084 ,  A61K9/0053 ,  A61K9/127 ,  A61K31/10 ,  A61K31/12 ,  A61K31/138 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/365 ,  A61K31/404 ,  A61K31/407 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4412 ,  A61K31/444 ,  A61K31/506 ,  A61K31/517 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/593 ,  A61K31/7072 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  B65D71/0085 ,  B65D75/002 ,  B65D75/36 ,  B65D75/366 ,  B65D75/368 ,  A61K2300/00

摘要： In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.

公开(公告)号：EP2665480A2

公开(公告)日：2013-11-27

申请号：EP12736283.8

申请日：2012-01-18

申请人： Vicus Therapeutics, LLC

发明人： MAKI, John ,  BASCOMB, Newell ,  TURNER, Timothy, J. ,  YOUNG, Fredric

IPC分类号： A61K31/455 ,  A61K31/20 ,  A61K31/133 ,  A61K9/06 ,  A61K9/70 ,  A61K9/12

CPC分类号： A61K31/7068 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/133 ,  A61K31/20 ,  A61K31/337 ,  A61K31/404 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517

摘要： In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising combinations of beneficial ingredients that in alternative embodiments are serviceable as therapies or palliatives for treating, preventing or improving conditions, states and disease symptoms involving the use of targeted protein kinase inhibitors such as Multi-Kinase Inhibitors (MKIs) or Epidermal Growth Factor Receptor (EGFR) Inhibitors (EGFRIs), or the use of other oral oncolytics, such as capcitabine or erlotinib, known to be associated with drug-induced dermatological toxicity, e.g., in the amelioration or treatment of a cancer, a dermatitis, a rosacea, an eczema, an ichthyosis, or a related condition; and methods for making and using these compositions; and methods for making and using these compositions.

公开(公告)号：EP3164121A1

公开(公告)日：2017-05-10

申请号：EP15814187.9

申请日：2015-07-01

申请人： Vicus Therapeutics, LLC

发明人： MAKI, John ,  BASCOMB, Newell ,  YOUNG, Fredric

IPC分类号： A61K31/00 ,  A61P35/00

CPC分类号： A61K31/407 ,  A61K31/138 ,  A61K31/155 ,  A61K31/195 ,  A61K31/197 ,  A61K31/341 ,  A61K31/4045 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/473 ,  A61K45/06 ,  A61K2300/00

摘要： In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices for treating, preventing or ameliorating a tumor or a cancer, and methods for treating, preventing or ameliorating a tumor or a cancer. In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices comprising: a beta adrenergic receptor antagonist (a “beta blocker”); a non-steroidal anti-inflammatory drug (a NSAID); and a therapeutic agent, compound or composition comprising: a H2-receptor antagonist (H2RA), a melatonin (or an N-acetyl-5-methoxy-tryptamine), a metformin, a quinoline (e.g., chloroquine), an immune checkpoint blockade agent, or an agent that blocks the interaction between a transmembrane programmed cell death 1 protein, or any combination thereof. In alternative embodiments, the therapeutic combinations of therapeutic agents or drugs further comprise an anti-cancer or anti-tumor antibody, a cytokine, and/or a chemotherapeutic agent.

摘要翻译： 在替代实施例中，提供了治疗组合，药物组合物，制剂，试剂盒和用于治疗，预防或改善肿瘤或癌症的装置和方法用于治疗，预防或改善肿瘤或癌症。 在替代实施例中，提供了治疗组合，药物组合物，制剂，试剂盒和装置，其包括：β肾上腺素受体拮抗剂（一个“β阻滞剂”）; 非甾体抗炎药（NSAID一个）; 和治疗剂，化合物或组合物，其包括：H2受体拮抗剂（H2RA），褪黑激素（或N-乙酰基-5-甲氧基 - 色胺），二甲双胍，免疫检查点封锁喹啉（例如，氯喹） 剂或试剂没有蛋白块的跨膜程序性细胞死亡1，或它们的任何组合之间的相互作用。 在可替代的实施方案中，治疗剂或药物的治疗组合的抗癌或抗肿瘤抗体，细胞因子，和/或化疗剂的进一步包含。

公开(公告)号：EP3028743A2

公开(公告)日：2016-06-08

申请号：EP15191023.9

申请日：2009-03-05

申请人： Vicus Therapeutics, LLC

发明人： BASCOMB, Newell ,  MAKI, John ,  YOUNG, Frederic

IPC分类号： A61P35/00 ,  A61K31/195 ,  A61K45/06 ,  A61K31/00 ,  A61K31/407 ,  A61K31/138

CPC分类号： A61K39/39558 ,  A23L33/10 ,  A23V2002/00 ,  A61J1/035 ,  A61J1/10 ,  A61J3/02 ,  A61J3/06 ,  A61J3/07 ,  A61J3/08 ,  A61J3/10 ,  A61J7/0084 ,  A61K9/0053 ,  A61K9/127 ,  A61K31/10 ,  A61K31/12 ,  A61K31/138 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/365 ,  A61K31/404 ,  A61K31/407 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4412 ,  A61K31/444 ,  A61K31/506 ,  A61K31/517 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/593 ,  A61K31/7072 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  B65D71/0085 ,  B65D75/002 ,  B65D75/36 ,  B65D75/366 ,  B65D75/368 ,  A61K2300/00

摘要： In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.

摘要翻译： 在替代实施方案中，本发明提供用于治疗癌症或由功能障碍性细胞引起的任何病状的组合物和方法，治疗癌症或由功能障碍性细胞引起的任何病症的副作用，例如粘膜炎治疗（例如，用于口腔粘膜炎;消化性粘膜炎;食管 粘膜炎;肠粘膜炎）。 在替代实施方案中，本发明提供了可以单独使用或与其它医学疗法如癌症化学疗法和放射治疗组合使用的细胞保护产物。